CLINICAL TRIAL CONSENTS:

ACTG Studies

 

Pre-Screen IC V2 4/12/16 *EFFECTIVE 3/23/17

Cryopreservation IC V9 1/25/10 *EFFECTIVE 5/22/17

A5128 V4 IC V9 8/24/17 *EFFECTIVE 9/21/17

A5315 V3 Cohort 4 IC V2 3/16/17 *EFFECTIVE 7/20/17

A5320 V2 IC V8 5/16/17 *EFFECTIVE 11/9/17

A5321 V2 IC V8 10/13/16 *EFFECTIVE 10/20/16

A5322 V2 IC V6 3/27/17 *EFFECTIVE 4/5/17

A5324 V2 IC V6 9/12/17 *EFFECTIVE 12/13/17

SPIRIT V1 IC V1 7/13/16 *EFFECTIVE 10/25/16

A5329 V2 IC V6 7/21/17 *EFFECTIVE 8/23/17

A5332 V3 IC V9 5/17/17 *EFFECTIVE 5/24/17

A5333s V3 IC V5 1/26/17 *EFFECTIVE 2/2/17

A5335s V1 IC V4 7/21/17 *EFFECTIVE 8/3/17

A5336 V2 IC V3 10/5/16 *EFFECTIVE 3/27/17

A5341s V1 IC V4 3/23/17 *EFFECTIVE 11/13/17

A5350 V1 IC V3 3/15/16 *EFFECTIVE 3/31//16

A5353 V1 IC V2 10/21/15 *EFFECTIVE 10/10/16

A5354 V1 IC V2 4/26/17 *EFFECTIVE 6/7/17

A5354 Optional Evals V1 IC V2 4/26/17 *EFFECTIVE 6/7/17

A5361s V1 IC V2 5/18/17 *EFFECTIVE 5/30/17

Cocaine Use PET Scan IC V3 2/25/14 *EFFECTIVE 11/21/16

Industry Studies

AI438047 IC V4 11/17/16 *EFFECTIVE 1/4/17

AI438047 PG IC V2 11/15/16 *EFFECTIVE 1/4/17

C34 Gene Therapy IC V5 7/10/17 *EFFECTIVE 10/5/17

C34 Gene Therapy LTFU IC V2 5/1/17 *EFFECTIVE 5/22/17

EBOV-001 IC V3 6/30/16 *EFFECTIVE 8/8/16

Ebola Plasma IC V3 5/24/17 *EFFECTIVE 6/1/17

EV Biomarkers - Dr. Mohler IC V2 3/16/16 *EFFECTIVE 4/4/17

Gilead US248-0122 IC5 4/5/17 *EFFECTIVE 5/2/17

Gilead US248-0123 IC5 4/5/17 *EFFECTIVE 5/1/17

Gilead US366-1160 IC 8/17/16 *EFFECTIVE 9/1/16

Gilead US366-1160Addendum IC 8/4/16 *EFFECTIVE 8/17/16

Gilead US366-1216 IC 8/17/16 *EFFECTIVE 9/1/16

Gilead US366-1216 Addendum IC 8/4/16 *EFFECTIVE 8/17/16

Gilead US366-1216 Dexa IC 5/13/16 *EFFECTIVE 6/20/16

Gilead US366-1992 IC 1/9/17 *EFFECTIVE 1/18/17

Gilead US366-1992 Pregnancy IC 9/20/16 *EFFECTIVE 10/19/16

Gilead US380-1489 IC 11/4/16 *EFFECTIVE 11/9/16

Gilead US380-1489Addendum IC 11/8/17 *EFFECTIVE 11/16/17

Gilead US380-1489 Triumeq Insert *EFFECTIVE 7/20/17

Gilead US380-1489 Pregnancy IC 11/3/15 *EFFECTIVE 12/9/15

Gilead US380-1490 IC 11/4/16 *EFFECTIVE 11/9/16

Gilead US380-1490Addendum IC 11/29/17 *EFFECTIVE 12/6/17

Gilead US380-1490 Tivicay Insert *EFFECTIVE 4/22/16

Gilead US380-1490 Pregnancy IC 11/3/15 *EFFECTIVE 12/10/15

IRC005 V3 IC V7 6/30/17 *EFFECTIVE 10/5/17

Leukapheresis - Reservoirs IC V2 12/1/15 *EFFECTIVE 10/12/17

Merck MK-1439A-021 IC 7/28/17 *EFFECTIVE 8/3/17

Merck MK-1439A-021 ext IC 7/28/17 *EFFECTIVE 8/3/17

Merck MK-1439A-021 FBR IC 6/16/15 *EFFECTIVE 6/22/15

Merck MK-1439A-021Clincard IC 2/5/15 *EFFECTIVE

Merck MK-1439A-021Clincard ext IC 11/18/16 *EFFECTIVE 2/8/17

Merck MK-1439A-024 IC 7/5/17 *EFFECTIVE 7/10/17

Merck MK-1439A-024 ext IC 7/5/17 *EFFECTIVE 7/10/17

Merck MK-1439A-024 Clincard IC 1/27/15 *EFFECTIVE 9/26/16

Merck MK-1439A-024 Clincard ext IC 1/27/15 *EFFECTIVE 11/7/16

Merck MK-1439A-024 FBR IC 6/16/15 *EFFECTIVE 6/22/15

Pfizer Poem A4001067 IC V5 3/21/12 *EFFECTIVE 2/28/13

Pfizer Poem A4001067 Pregnancy Partner Release *EFFECTIVE 11/4/16

Sangamo (znf) LTFU V4 1/8/14 *EFFECTIVE 10/12/15

Sangamo II (m-rna) LTFU V3 7/22/16 *EFFECTIVE 3/6/17

Sangamo SB-728mR Cohort 1 V12 2/24/17 *EFFECTIVE 7/20/17

Sangamo SB-728mR Cohort 2/3 V3 2/24/17 *EFFECTIVE 7/20/17

Virxsys/Adapt LTFU 3/30/12 - *EFFECTIVE 7/7/16

VRC 500 IC V1 10/21/16 - *EFFECTIVE 12/5/16

VRC 607 IC V3 6/5/17 - *EFFECTIVE 6/23/17

Zika-001 V1.1 6/13/16 - *EFFECTIVE 7/21/16

Zika Plasma IC V3 7/24/17 - *EFFECTIVE 10/9/17

 
 


About Penn Medicine   Contact Us   Site Map   Privacy Statement   Legal Disclaimer   Terms of Use

Penn Medicine, Philadelphia, PA 800-789-PENN © 2017, The Trustees of the University of Pennsylvania